Rapid Micro Biosystems to Showcase Automation Solutions at H.C. Wainwright Global Investment Conference
PorAinvest
miércoles, 3 de septiembre de 2025, 4:30 am ET1 min de lectura
RPID--
Rapid Micro Biosystems specializes in providing mission-critical automation solutions for healthcare product manufacturing. The company's flagship product, the Growth Direct system, automates and modernizes the microbial quality control (MQC) testing workflows used in large-scale pharmaceutical manufacturing operations. This system brings the quality control lab to the manufacturing floor, enhancing efficiency, accuracy, and compliance with data integrity regulations [1][2].
The company's headquarters are located in Lexington, Massachusetts, with U.S. manufacturing in Lowell, Massachusetts. Additionally, Rapid Micro Biosystems has global locations in Switzerland, Germany, and the Netherlands. For more information, investors can visit the company's website at [www.rapidmicrobio.com](http://www.rapidmicrobio.com) or follow the company on X (formerly known as Twitter) at [@rapidmicrobio](http://twitter.com/rapidmicrobio) or on LinkedIn [1][2].
References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3143190/33206/en/Rapid-Micro-Biosystems-to-Present-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html
[2] https://www.biospace.com/press-releases/rapid-micro-biosystems-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference
Rapid Micro Biosystems will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. The company specializes in automation solutions for healthcare product manufacturing and will showcase its innovative technologies that facilitate efficient manufacturing and safe release of healthcare products. Investors can access a live webcast through the company's investor relations website.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID), an innovative life sciences technology company, has announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York, NY. The presentation is scheduled for Tuesday, September 9, 2025, at 11:00 a.m. ET. Investors and financial professionals can access a live webcast of the presentation through the company's investor relations website at [https://investors.rapidmicrobio.com/](https://investors.rapidmicrobio.com/) [1][2].Rapid Micro Biosystems specializes in providing mission-critical automation solutions for healthcare product manufacturing. The company's flagship product, the Growth Direct system, automates and modernizes the microbial quality control (MQC) testing workflows used in large-scale pharmaceutical manufacturing operations. This system brings the quality control lab to the manufacturing floor, enhancing efficiency, accuracy, and compliance with data integrity regulations [1][2].
The company's headquarters are located in Lexington, Massachusetts, with U.S. manufacturing in Lowell, Massachusetts. Additionally, Rapid Micro Biosystems has global locations in Switzerland, Germany, and the Netherlands. For more information, investors can visit the company's website at [www.rapidmicrobio.com](http://www.rapidmicrobio.com) or follow the company on X (formerly known as Twitter) at [@rapidmicrobio](http://twitter.com/rapidmicrobio) or on LinkedIn [1][2].
References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3143190/33206/en/Rapid-Micro-Biosystems-to-Present-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html
[2] https://www.biospace.com/press-releases/rapid-micro-biosystems-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios